Department of Urology, Yan'an People's Hospital, Yan'an, China.
Department of Neurology, Affiliated Hospital of Yan'an University, Yan'an, China.
BMC Urol. 2022 Nov 25;22(1):195. doi: 10.1186/s12894-022-01143-z.
Unpredicted postoperative recurrence of prostate cancer, one of the most common malignancies among males worldwide, has become a prominent issue affecting patients after treatment. Here, we investigated the correlation between the serum miR-148a-3p and miR-485-5p expression levels and cancer recurrence in PCa patients, aiming to identify new biomarkers for diagnosis and predicting postoperative recurrence of prostate cancer.
A total of 198 male PCa cases treated with surgery, postoperative radiotherapy, and chemotherapy were involved in the presented study. Serum levels of miR-148a-3p and miR-485-5p were measured before the initial operation for the involved cases, which were then followed up for two years to monitor the recurrence of cancer and to split the cases into recurrence and non-recurrence groups. Comparison of the relative expressions of serum miR-148a-3p and miR-485-5p were made and related to other clinic pathological features.
Pre-surgery serum levels of miR-148a-3p in patients with TNM stage cT1-2a prostate cancer (Gleason score < 7) were significantly lower (P < 0.05) than levels in patients with TNM Classification of Malignant Tumors (TNM) stage cT2b and higher prostate cancer (Gleason score ≥ 7). pre-surgery serum levels of miR-485-5p in patients with TNM stage cT1-2a prostate cancer (Gleason score < 7) were significantly higher (P < 0.05) than in patients with TNM stage cT2b and higher cancer (Gleason score ≥ 7). Serum miR-148a-3p level in recurrence group is higher than the non-recurrence group (P < 0.05) while serum miR-485-5p level in recurrence group is lower than non-recurrence group (P < 0.05). ROC curve analysis showed the AUCs of using miR-148a-3p, miR-485-5p, and combined detection for predicting recurrence of prostate cancer were 0.825 (95% CI 0.765-0.875, P < 0.0001), 0.790 (95% CI 0.726-0.844, P < 0.0001), and 0.913 (95% CI 0.865-0.948, P < 0.0001).
Pre-surgery serum miR-148a-3p level positively correlates while miR-485-5p level negatively correlates with prostate cancer's progressing and postoperative recurrence. Both molecules show potential to be used for predicting postoperative recurrence individually or combined.
前列腺癌是全球男性最常见的恶性肿瘤之一,其术后复发是影响患者治疗后生活质量的一个突出问题。本研究旨在探讨血清 miR-148a-3p 和 miR-485-5p 表达水平与前列腺癌患者癌症复发之间的相关性,以期为前列腺癌的诊断和预测术后复发提供新的生物标志物。
本研究共纳入 198 例接受手术、术后放化疗的前列腺癌男性患者。对入组患者进行初始手术前的血清 miR-148a-3p 和 miR-485-5p 水平检测,随后对患者进行为期两年的随访,以监测癌症复发情况,并将患者分为复发组和非复发组。比较两组患者血清 miR-148a-3p 和 miR-485-5p 的相对表达水平,并与其他临床病理特征进行相关分析。
术前血清 miR-148a-3p 水平在 TNM 分期 cT1-2a 前列腺癌(Gleason 评分<7)患者中明显低于 TNM 分期 cT2b 和更高期前列腺癌(Gleason 评分≥7)患者(P<0.05)。术前血清 miR-485-5p 水平在 TNM 分期 cT1-2a 前列腺癌(Gleason 评分<7)患者中明显高于 TNM 分期 cT2b 和更高期前列腺癌(Gleason 评分≥7)患者(P<0.05)。复发组患者血清 miR-148a-3p 水平高于非复发组(P<0.05),而复发组患者血清 miR-485-5p 水平低于非复发组(P<0.05)。ROC 曲线分析显示,miR-148a-3p、miR-485-5p 及联合检测预测前列腺癌复发的 AUC 分别为 0.825(95%CI:0.765-0.875,P<0.0001)、0.790(95%CI:0.726-0.844,P<0.0001)和 0.913(95%CI:0.865-0.948,P<0.0001)。
术前血清 miR-148a-3p 水平升高与前列腺癌进展及术后复发呈正相关,而 miR-485-5p 水平与前列腺癌进展及术后复发呈负相关。两者均有潜力单独或联合用于预测术后复发。